Lupin is currently trading at Rs. 923.50, up by 20.05 points or 2.22% from its previous closing of Rs. 903.45 on the BSE.
The scrip opened at Rs. 902.05 and has touched a high and low of Rs. 933.00 and Rs. 898.45 respectively. So far 150138 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 854.00 on 20-Dec-2021.
Last one week high and low of the scrip stood at Rs. 969.00 and Rs. 897.65 respectively. The current market cap of the company is Rs. 41599.89 crore.
The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.
Lupin had entered into a partnership with Shenzhen Foncoo Pharmaceutical Company (Foncoo). This is Lupin’s first partnership arrangement in China and reinforces its commitment to bringing high quality generic and complex generic medicines to patients around the world.
With China’s growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs of the Chinese population by providing high quality generic and complex generic products.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.